Core Viewpoint - The company expects a net profit attributable to the parent company of -292 million yuan for the fiscal year 2025, indicating continued financial challenges ahead [1] Financial Performance - The company anticipates achieving an operating revenue of 37.2452 million yuan in 2025, which suggests a significant struggle to reach profitability [1] - The expected losses in 2025 are primarily influenced by the intensity of research and development investments alongside the composition of revenue [1]

Financial Projections - The company expects a total profit of -291.82 million yuan for the year 2025, with a net profit attributable to shareholders of -292.20 million yuan, and a net profit of -304.41 million yuan after deducting non-recurring gains and losses [3]. - The projected operating revenue for 2025 is 37.25 million yuan, which is below 100 million yuan [3]. - In 2024, the company reported a total profit of -240.20 million yuan and a net profit attributable to shareholders of -240.20 million yuan [5]. - The operating revenue for 2024 was 168.79 million yuan [7]. Research and Development - The company's R&D investment remains high, with key clinical projects making significant progress, including ongoing Phase III clinical trials for D-0502 and D-2570 [8]. - The company is also advancing two innovative preclinical candidates, YF087 and YF550, which show promising anti-tumor potential [8]. Revenue and Costs - The revenue from technology licensing and cooperation has varied compared to 2024, and is currently insufficient to cover costs and expenses, leading to expected continued losses in 2025 [9]. - The company emphasizes that its core business and competitive strengths have not experienced significant adverse changes despite the projected losses [9]. Financial Reporting - The financial data provided is preliminary and has not been audited by registered accountants, with the final figures to be confirmed in the official audited annual report [10][11].

资料显示，益方生物科技(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路67弄4号210室,香港 湾仔皇后大道东183号合和中心46楼，成立日期2013年1月11日，上市日期2022年7月25日，公司主营业 务涉及创新药物的研发、生产和销售。主营业务收入构成为：技术授权和技术合作收入100.00%。 融资方面，益方生物当日融资买入3862.11万元。当前融资余额2.23亿元，占流通市值的1.50%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，益方生物1月26日融券偿还5900.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量3.72万股，融券余额95.61万元，超过近一年90%分位水平，处于高位。 1月26日，益方生物跌2.84%，成交额4.68亿元。两融数据显示，当日益方生物获融资买入额3862.11万 元，融资偿还2244.42万元，融资净买入1617.69万元。截至1月26日，益方生物融资融券余额合计2.24亿 元。 截至9月30日，益方生物股东户数1.24万，较上期增加26.17%；人均流通股33810股，较上期减少 17.52%。2025年1月-9月， ...

Core Viewpoint - On January 26, a total of 8 listed companies will have their restricted shares unlocked, with a total market value of approximately 2.11 billion yuan [1] Summary by Category Restricted Share Unlocking - The companies involved in the unlocking of restricted shares include: - Meili Eco (000010) with 45.48 million shares from equity incentive restrictions - Jiadian Co. (000922) with 236,500 shares from equity incentive restrictions - Nanjing Pharmaceutical (600713) with 5.43 million shares from equity incentive restrictions - Nuofushin (002215) with 4.43 million shares from equity incentive restrictions - Great Wall Motors (601633) with 13.67 million shares from equity incentive restrictions - Xutian Salt Industry (600929) with 513,600 shares from equity incentive restrictions - Tianzheng Electric (605066) with 462,500 shares from equity incentive restrictions - Yifang Bio (688382) with 161 million shares [1]

格隆汇1月26日｜Wind数据显示，周一（1月26日），共有8家公司限售股解禁，合计解禁量为1.64亿 股，按最新收盘价计算，合计解禁市值为44.49亿元。从解禁量来看，益方生物-U、欧普泰、云天励飞- U解禁量居前，解禁股数分别为1.61亿股、95.21万股、77.67万股。从解禁市值来看，益方生物-U、荣 昌生物、云天励飞-U解禁市值居前，解禁市值分别为42.51亿元、7846.56万元、6759.79万元。从解禁股 数占总股本比例来看，益方生物-U、欧普泰、云天励飞-U解禁比例居前，解禁比例分别为27.79%、 1.19%、0.22%。 ...

Core Insights - On January 26, a total of 5 companies released restricted shares, amounting to 1.63 million shares and a total market value of 4.43 billion yuan [1][2] Group 1: Companies with Highest Share Unlocking - Yifang Biotechnology had the largest share unlock with 161 million shares, representing 27.79% of its total share capital, with a market value of 4.25 billion yuan [1][2] - Rongchang Biotechnology unlocked 767,200 shares, accounting for 0.14% of its total share capital, with a market value of approximately 7.85 million yuan [1][2] - Yuntian Lifei released 776,700 shares, which is 0.22% of its total share capital, with a market value of around 6.76 million yuan [1][2] Group 2: Additional Companies - Zhongke Chuangda unlocked 368,700 shares, representing 0.08% of its total share capital, with a market value of approximately 2.98 million yuan [2] - Xue Tian Salt Industry released 487,800 shares, accounting for 0.03% of its total share capital, with a market value of about 297,530 yuan [2]

Group 1: US-China Relations - US President Trump is expected to visit China in April, with Chinese leaders planning to visit the US by the end of the year, highlighting the importance of high-level diplomacy in stabilizing US-China relations [2][3] Group 2: Commercial Space Industry - SpaceX aims to achieve fully reusable rocket technology with its Starship, potentially reducing space access costs by 99% to below $100 per pound [2] - Beijing's measures to promote the development and utilization of commercial satellite remote sensing data from 2026 to 2030 include optimizing financial support and encouraging investment in quality projects [3] - The commercial space economy is projected to reach $1.8 trillion by 2035, driven by new infrastructure and applications in the space sector [4] Group 3: Stock Market and IPOs - Recent rumors about tightening regulations for companies seeking to list in Hong Kong have been denied, confirming that current overseas listing policies remain unchanged [3] - The China Securities Regulatory Commission (CSRC) has approved IPO registrations for three companies, indicating ongoing market activity [11] - A total of 28 companies are set to unlock 796 million shares this week, with a total market value of approximately 40.97 billion yuan [12][13]

Economic Indicators - The January PMI data will be released on January 31, with December's PMI at 50.1%, an increase of 0.9 percentage points, marking a return to the expansion zone after eight months below 50% [1][10]. Monetary Policy - The Federal Reserve is expected to announce its interest rate decision next week, with a 95% probability that rates will remain unchanged during the January meeting [2][10]. - Citic Securities believes that the criminal investigation into Powell will not pressure the Fed into aggressive rate cuts, predicting a pause in rate cuts for January [2][10]. Central Bank Operations - The central bank conducted a reverse repo operation of 11,810 billion yuan this week, with a net injection of 2,295 billion yuan after 9,515 billion yuan matured [3][11]. - Next week, 11,810 billion yuan in reverse repos will mature, with specific maturities scheduled throughout the week [3][11]. Stock Market Developments - Over 40 billion yuan in market value of restricted shares will be unlocked next week, with January 27 being the peak day for unlocks [4][12]. - The top three companies by unlock market value are Haibo Sichuang (231.54 billion yuan), Fostar (53.67 billion yuan), and Yifang Bio-U (42.51 billion yuan) [4][12]. New Stock Opportunities - Three new stocks will be issued next week: Beixin Life on January 26, and Linping Development and Electric Science Blue Sky on January 30 [7][14]. - The subscription details for the new stocks include a price of 17.52 yuan for Beixin Life and subscription limits for the other two stocks [8][15].

Core Viewpoint - Yifang Biotechnology has submitted an application for a mainboard listing on the Hong Kong Stock Exchange, amid a wave of License-out deals in the domestic innovative drug sector, but faces significant challenges including ongoing losses, business model risks, and governance concerns [1][7]. Business Model and Financial Performance - Yifang Biotechnology relies heavily on the License-out model, with its two marketed products, Beifuzi and Goresir, exclusively licensed to leading companies, BeiGene and Zhenhua Tianqing [2][8]. - Revenue figures show that from 2023 to the first three quarters of 2025, the company generated revenues of CNY 186 million, CNY 169 million, and CNY 30.89 million, all from licensing agreements [2][8]. - In 2023, over 96% of revenue came from a CNY 180 million milestone payment for Beifuzi, while in 2024, the focus shifted to a CNY 151 million milestone payment for Goresir [2][8]. - Despite these revenues, the company has not achieved profitability, reporting net losses of CNY 284 million, CNY 240 million, and CNY 181 million for 2023, 2024, and the first three quarters of 2025, respectively [2][8]. Accounts Receivable Issues - A significant issue arose when BeiGene delayed a CNY 180 million milestone payment for Beifuzi, leading to a nearly two-year overdue situation [3][9]. - Although the revenue was recognized in 2023, cash flow was delayed, resulting in a CNY 18 million bad debt provision in 2024 [3][9]. Financial Position and Fundraising - As of September 30, 2025, Yifang Biotechnology had CNY 670 million in cash and cash equivalents, CNY 700 million in time deposits, and CNY 153 million in financial assets, totaling CNY 1.523 billion in liquid assets [4][10]. - The company has CNY 1 billion of unutilized funds from its previous fundraising round and has invested CNY 761 million in cash management [4][10]. - Despite a strong cash position, the rationale for seeking additional fundraising is questioned [4][10]. Governance and Shareholding Structure - The company's governance structure is under scrutiny, with a trend of shareholding dilution following the expiration of a joint action agreement among key executives [5][11]. - The combined shareholding of the founders decreased from 28.58% to 27.26% after the agreement ended, raising concerns about control [5][11]. - A significant number of shares (approximately 161 million, or 27.79% of total shares) will be unlocked in January 2026, potentially leading to market pressure [5][11]. Executive Compensation - The total annual salary for key executives exceeded CNY 25 million from 2023 to 2024, which is considered high relative to the company's ongoing losses [6][12]. - Balancing executive incentives with shareholder returns and sustainable development remains a governance challenge [6][12].

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.01% on January 22, with Yifang Bio leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Dongya Pharmaceutical (605177) with a closing price of 22.95, up 6.89% [1] - Warner Pharmaceuticals (688799) at 50.35, up 6.52% [1] - Haixin Co. (600851) at 8.00, up 5.26% [1] - Conversely, Yifang Bio (688382) saw a significant decline of 6.03%, closing at 25.87 [2] - Other notable decliners included: - Xingqi Eye Medicine (300573) down 5.27% at 78.36 [2] - Dize Pharmaceutical (688192) down 4.43% at 59.05 [2] Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 1.78 billion yuan from institutional investors, while retail investors saw a net inflow of 1.6 billion yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Key stocks with significant capital flow include: - Tonghua Golden Horse (000766) with a net inflow of 32.99 million yuan from institutional investors [3] - Yifang Bio (688382) had a net outflow of 9.61 million yuan from institutional investors [3] - Haixin Co. (600851) saw a net inflow of 18.22 million yuan from institutional investors [3]